Suite 802, West Tower, OmniVision
88 Shangke Road
Tel: 86-21-6057 8000
I-Mab is a dynamic and fast-growing global player committed to developing innovative biologics in the areas of immuno-oncology and immuno-inflammation through internal R&D capabilities and global partnerships. I-Mab's pipeline is driven by the company's development strategy to address unmet needs in China and to bring innovative assets to the world.
CEO: Jingwu Zang
CSO: Taylor Guo
168 articles about I-Mab
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
I-Mab reported interim data from an ongoing clinical trial of lemzoparlimab in combination with rituximab in heavily treated patients with relapsed or refractory non-Hodgkin's lymphoma, at the 63rd American Society of Hematology Annual Meeting.
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma
I-Mab (the "Company") (Nasdaq: IMAB), today announced that it will hold a call with investors at 8:00 a.m. EST on December 14 to provide an in-depth analysis of the most recent clinical data from an ongoing clinical trial of lemzoparlimab in combination with rituximab in relapsed or refractory non-Hodgkins's lymphoma.
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
I-Mab today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimer's disease.
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
I-Mab today announced that the Board of Directors of the Company (the "Board") approved a motion to pursue the listing of the Company's ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Dual Listing").
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
I-Mab today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab (Tecentriq®) in patients with ovarian cancer and other selected advanced or metastatic solid tumors.
Scientists from Brigham and Women's Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer's disease.
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
I-Mab announced that it has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group, a leading China pharmaceutical company specialized in and committed to pediatric medicines, for the development, manufacturing and commercialization of I-Mab's highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China.
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that an abstract summarizing the most recent clinical data from an ongoing clinical trial of its differentiated CD47 antibody lemzoparlimab, will be presented at the 63rd American Society of Hematology Annual Meeting, taking place December 11 – 14, 2021.
I-Mab Announces Upcoming Participation at November 2021 Conferences
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its participation in the following conferences in November.
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
I-Mab and ABL Bio, Inc. jointly announced that data from the preclinical studies of TJ-CD4B/ABL111 and TJ-L14B/ABL503, will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021), taking place November 12 – 14, 2021.
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021
The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
I-Mab to host conference calls and webcasts on August 31, 2021. A Mandarin session conference call will be held at 7:00 a.m. ET, and an English session conference call will be held at 8:00 a.m. ET.
I-Mab Announces Upcoming Participation at September 2021 Conferences
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in September.
I-Mab Announces Establishment of Environmental, Social and Governance Committee
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors approved establishment of an ESG Committee.
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021
I-Mab today announced it will provide business and corporate updates and report financial results for the six months ended June 30, 2021, before the market opens on Tuesday, August 31, 2021.
Clinical Catch-Up: August 9-13
8/16/2021There was plenty of clinical trial updates last week. Here’s a look.
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
I-Mab today announced positive interim data from its U.S. phase 2/3 study (NCT04341116) of plonmarlimab (also known as TJM2 or TJ003234) for the treatment of cytokine release syndrome (CRS) in patients with severe COVID-19.
I-Mab announced positive interim data from its U.S. Phase II/III clinical trial of plonmarlimab for treatment of cytokine release syndrome in severe COVID-19.
Clinical Catch-Up: August 2-6
8/9/2021It was a busy week for clinical trial announcements. Take a look.